Aldeyra Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$35.3 | -$60.1 | -$42.8 | -$62.7 | -$56.2 |
| Net income | -$33.8 | -$55.9 | -$37.5 | -$62.0 | -$57.8 |
| Cash Flow Statement | |||||
| Free cash flow | — | — | -$30.3 | -$56.7 | -$42.6 |
Shares outstanding 60.3M · Free float 78.5%
Annual filing data through FY ended December 31, 2025; float as of October 28, 2026.
Aldeyra Narrows Third-Quarter Loss After R&D Cut